Key result
Obicetrapib reduces LDL-C by ~37% compared to placebo in high-risk dyslipidemia.
Why the study?
Earlier CETP inhibitors showed inconsistent cardiovascular outcomes and safety concerns, so the efficacy and safety of obicetrapib remain under active investigation.
Does obicetrapib reduce atherogenic lipids, including LDL-C, in adult patients with dyslipidemia and/or high cardiovascular risk?
Meta-Analysis (n=3,381)
Randomized
Does obicetrapib reduce atherogenic lipids, including LDL-C, in adult patients with dyslipidemia and/or high cardiovascular risk?
Mean Difference: -37.21 (95% CI -41.53–-32.9)
p-value: p=<0.01
Obicetrapib significantly and robustly reduces atherogenic lipids, including LDL-C and Lp(a), with a favorable safety profile and potential reduction in new-onset diabetes, representing a promising oral adjunctive therapy for dyslipidemia.
Supports obicetrapib as adjunctive therapy in dyslipidemia; extends prior CETP inhibitor data with consistent efficacy and safety.
Obicetrapib is a novel cholesteryl ester transfer protein (CETP) inhibitor with promising lipid-lowering effects. While earlier CETP inhibitors have shown inconsistent cardiovascular outcomes and safety concerns, the efficacy and safety of obicetrapib remain under active investigation. We systematically searched PubMed, Embase, and Cochrane Central databases for randomized controlled trials (RCTs) comparing obicetrapib versus placebo in adults with dyslipidemia or at high cardiovascular risk. We pooled mean differences (MDs) with 95 % confidence intervals (CI) with a random effects model. We used R software version 4.4.2 for statistical analysis. We included 7 RCTs comprising 3381 participants, of whom 2151 (63 %) received obicetrapib. The mean age was 64.3 years, and 36 % were women. Compared with placebo, obicetrapib significantly reduced mean LDL-C (MD: -37.21 %; 95 % CI: -41.53 to -32.90; p < 0.01; I 2 =64 %), lipoprotein(a) (MD: -37.16 %; 95 % CI: -43.63 to -30.70; p < 0.01, I 2 =48 %), apolipoprotein B (MD: -24.65 %; 95 % CI: -28.71 to -20.59; p < 0.01; I²=83 %), non-HDL-C (MD: -31.90 %; 95 % CI: -34.81 to -28.99; p < 0.01; I 2 =0 %), and triglyceride levels (MD: -7.21 %; 95 % CI: -11.13 to -3.30; p < 0.01; I 2 =0 %). Interestingly, obicetrapib also reduced the incidence of new-onset diabetes (RR: 0.88; 95 % CI: 0.80 to 0.97; p = 0.01; I²=0 %). In contrast, obicetrapib significantly increased HDL-C (MD: 142.17 %; 95 % CI: 117.56 to 166.78; p < 0.01; I 2 =98.3 %), total cholesterol (MD: 11.94 %; 95 % CI: 5.61 to 18.28; p = 0.01; I 2 =91 %), and apolipoprotein A1 concentrations (MD: 52.76 %; 95 % CI: 41.87 to 63.66; p < 0.01; I²=94 %). There were no significant differences in adverse events. Among patients with dyslipidemia and/or high cardiovascular risk, obicetrapib significantly reduces LDL-C, lipoprotein(a), apolipoprotein B, and non-HDL-C. No significant differences were observed in adverse events, supporting the favorable safety profile of obicetrapib.
No takes yet. Share an insight, caveat, or question.
Arrighini et al. (2025) conducted a meta-analysis in Dyslipidemia and/or high cardiovascular risk (n=3,381). Obicetrapib vs. Placebo was evaluated on Mean change in LDL-C from baseline (MD -37.21%, 95% CI -41.53 to -32.90, p=<0.01). Obicetrapib significantly reduced mean LDL-C by 37.21% compared to placebo in adult patients with dyslipidemia and/or high cardiovascular risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: